Indo-Bangla Pharmaceuticals Ltd. has signed a Memorandum of Understanding (MoU) with Salar Yousafzai Pharma Ltd., an Afghanistan-based company, for the export of pharmaceutical products to the Afghan market.
The MoU, approved at a board meeting on 8 July 2025, grants exclusive distribution rights to Salar Yousafzai Pharma for a period of 15 years, effective until 2040. The agreement may be renewed upon mutual consent.
According to the disclosure on the Dhaka Stock Exchange, each shipment under the deal must have a minimum order value of $150,000. Payment terms require 40% to be made in advance via telegraphic transfer (TT), with the remaining 60% due before shipment. Deliveries will be executed on a Free on Board (FOB) Chattogram basis.
The company expects the partnership to boost export earnings in foreign currency, strengthen its financial position, and support long-term growth.
Established in 1954 and restructured as a public limited company, Indo-Bangla Pharmaceuticals has been listed on the Dhaka Stock Exchange since 2018. The firm manufactures a range of generic medicines and has expanded its portfolio across multiple therapeutic segments. In recent years, it has shifted focus towards overseas markets, aiming to diversify revenue and enhance competitiveness.
Company officials said the export agreement marks a strategic move to deepen its presence in regional markets and enhance shareholder value.
Indo-Bangla shares, with a face value of Tk10, began rallying from around Tk9 apiece on 23 June and briefly crossed Tk15 on Wednesday. However, the stock ended the day 0.7% lower at Tk14.10 amid profit-taking.